• Paid subscriptions to Moxian+ Business app offer China’s small business enterprises (SMEs) premium detailed analysis of consumer buying trends
• Moxian is projected to reach revenues of $24.1 million by FY2018, per SeeThruEquity report
• China’s has world’s largest mobile phone market representing 1.3 billion people, per Ministry of Industry and Technology data

Moxian, Inc. (NASDAQ: MOXC) employs a unique strategy in China’s online-to-offline (O2O) market. First, it signs up merchants to its paid Moxian+ Business app, then it uses the client’s list of consumers to effectively mine valuable data analytics. On the consumer side, it offers the Moxian+ User app. This platform has games, shopping, and social loyalty programs, enabling customers to earn prizes paid for with Moxian’s proprietary Mo-Coins and Mo-Points.

Moxian is a digital marketing company based in Shenzhen, China, which is converting its two apps to paid platforms. Its Moxian+ Business app, already serving some 31,600 small market enterprises (SMEs) in China, offers business merchants online transactions that are finalized at brick-and-mortar stores. Paid subscriptions have enhanced analytics of customers. The company also has 300,000 consumers on Moxian User. Mo-Talk, a Moxian proprietary voice-chat service, is a feature on both apps — designed to help customers and client merchants interact.

The result is that merchant clients learn more through data analytics while driving the revenue of Moxian through OEM licensing fees, sale commissions, mobile digital advertising, and targeted marketing campaigns. Premium analysis of data for business clients details buying patterns of customers. In February, 2017, SeeThruEquity (http://dtn.fm/1uxqL) projected that Moxian will reach $24.1 million in sales by fiscal year 2018.

According to the company’s SEC 10K annual report filing in December 2016 (http://dtn.fm/V5qta), when a business client purchases a Moxian + subscription, it is offered premium tools. These include detailed analytic reports and targeted messaging to consumers. To consumers, the company offers a game center that permits consumers to earn Mo-Points and a feature which enables subscribers to win vouchers and discounts.

All of this occurs in the largest mobile market in the world. China’s Ministry of Industry and Technology estimates that China has some 1.3 billion people on mobile phones, according to the SeeThruEquity report.

For more information, visit the company’s website at www.Moxian.com

• Pioneering, patent-pending solution helps prevent active shooter incidents
• Sales commitments exceeding $2.7 million in first three months of marketing
• Company quickly moving to global scale

It’s only been three months since Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) began marketing its game-changing, award-winning PATSCAN CMR™ concealed weapons detection system, and already the company has moved impressively close to global scale and to exceeding its goals, with orders placed that span four continents and confirmed sales commitments surpassing $2.7 million. Terror is a global problem, which makes Patriot One’s pioneering solution a global triumph.

Once a terrorist action is set into motion, there can never be a good outcome. That’s why Patriot One’s disruptive PATSCAN CMR is designed to help prevent active shooter incidents and other terror events from ever happening. The system instantly detects concealed weapons, even on moving targets, and then immediately alerts security personnel of the threat, so quick preventative action can be taken.

PATSCAN CMR operates by analyzing metal content and then relating it to a database of known weapons signatures, enabling the system to identify any individuals entering a venue possessing guns, knives, suicide vests or other weapons anywhere on their person. The benefits of this pioneering system are enormous, as it overcomes the limitations of current weapons scanning techniques and technologies, mitigates user error, eradicates compliance problems and more. PATSCAN CMR is also small, which allows it to be inconspicuously placed in doorways, hallways and other entry areas at any kind of facility—schools, hospitals, stadiums, etc. Because PATSCAN CMR can be covertly placed, individuals entering a venue have no idea they’re being scanned for weapons. At the same time, privacy isn’t an issue because the system does not capture any images of those it is scanning.

Good news travels fast, and news of Patriot One’s innovative, potentially lifesaving technology has spread quickly among investors and potential customers. In June, Patriot One announced three significant reseller agreements with companies that delivery security solutions to military, government, health care and commercial organizations: information technology communications contracting company JB Federal LLC; security solutions provider SENGEX; and Aotea Security Ltd., which is the provider of New Zealand’s only nationwide electronic security, electrical, fire and communications services solution.

These reseller agreements are evidence of just how much Patriot One’s terror-prevention solution is needed and how poignantly the company’s aim and message are resonating on a global level.

For more information, visit the company’s website at www.Patriot1Tech.com

Let us hear your thoughts: Patriot One Technologies, Inc. Message Board

• In the U.S., more than 5.3 million people suffer from Alzheimer’s disease, and 46 million around the world have it
• Alzheimer’s disease cost the U.S. more than $236 billion in 2016, and the global costs topped $600 billion
• In 2017, IGC acquired exclusive rights to an Alzheimer’s treatment, based on THC, from the University of South Florida
• Huge valuation growth potential in light of other Alzheimer’s and cannabis-based companies

India Globalization Capital, Inc. (NYSE MKT: IGC) has been working on phytocannabinoid-based therapies for various medical conditions for some time. Its drug development pipeline consists of treatments for seizures, neuropathic pain, and eating disorders, but one gaining attention is an experimental cannabis-based drug for Alzheimer’s disease, IGC-AD1. A University of South Florida patent was issued in July 2015. However, the study of using cannabis to treat the disease began long before that. A Molecular Pharmaceutics report (http://dtn.fm/A48in) suggested that cannabinoids could be useful in treating patients, back in 2008; that was long before a scientific study made a breakthrough in 2014, claiming tetrahydrocannabinol (THC) had the potential to be a therapeutic agent for Alzheimer’s in a published report released by the Journal of Alzheimer’s Disease.

In a recent Benzinga article (http://dtn.fm/GmO6t), the details of the study were highlighted. Scientists suggested that THC molecules, representing one of marijuana’s main chemical compounds, could bind to and break up amyloid-beta protein, which is associated with plaques that form around nerve cells. The effectiveness has not overruled any concerns regarding safety. Clinical trials, though, have found the side effects of THC to be mostly tolerable for patients, and proper doses have been correlated with positive results. Many Alzheimer’s patients have experienced reduced delusions or mood problems.

In the elderly, the disease is a leading cause of dementia. The number of cases is expected to increase and even triple within 50 years, adding to the hardship on the quality of life of individuals and the associated health care costs. Treatment options have aimed at slowing or halting the progression. With THC, studies have identified molecular mechanisms associated with how cannabinoid molecules have a direct effect on amyloid plaques in the brain and how the disease progresses.

The first pharmaceutical company listed on the NYSE to develop cannabis-based therapies for Alzheimer’s, IGC remains the only publicly-traded cannabis pharmaceutical stock to address the disease. Nonetheless, other studies have revealed therapeutic promise in this area. Researchers at the University of Bonn and the Hebrew University of Jerusalem tried cannabis on old mice with decreases in memory. A long term, low-dose regiment of cannabis restored their memory performance to that of a two-month old mouse. The results were published in the journal Nature Medicine.

Also, genetic activity at the molecular level, and brain tissue, became more like that of younger animals. This included an increase in nerve cell links in the brain. The study preceded clinical trials on humans, which have since yielded promising results.

Finally, and perhaps even more important from an investment standpoint, is IGC’s potential for market valuation growth, given the company’s pipeline of Hyalolex for Alzheimer’s and other phytocannabinoid-based therapies. Other companies focused on Alzheimer’s, such as AVXL, AXON, ACIU, and BIIB, sport market valuations in the hundreds of millions or even billions of dollars, while other cannabis-focused companies, such as CRBP and ZYNE, are already in the hundreds of millions.

To learn more about India Globalization Capital, its drug development pipeline, and its pursuit of cannabis-based therapies for Alzheimer’s patients, go to www.IGCInc.us

• First online Chinese language cannabidiol (CBD) health products store
• Yelp-style mobile app for locating dispensaries and discussing cannabis products in the U.S.
• Investor consultancy and financial news service

It appears that since antiquity, the Chinese have been aware of the therapeutic effect of cannabinoids. References in a manuscript with the authoritative title ‘Additional Records of Famous Physicians’, dating from the sixth century AD, point to their use as analgesics for “relieving impediment,” essentially the relief of pain. In a country with such a rich tradition of herbal remedies, cannabinoids have played an important role. Now, generations later, ChineseInvestors.com, Inc. (OTCQB: CIIX) continues the tradition of ‘Famous Physicians’ by expanding access to the medicinal benefits of cannabidiol (CBD), a non-psychotropic cannabinoid derived from hemp. The company operates the first online Chinese language CBD health product store. Now, two billion Chinese can order their medicine online and have it delivered to their homes.

The CBD CIIX plans to offer its customers will be extracted from hemp, which means the products will be entirely legal. Hemp, of course, is a variety of the cannabis sativa plant, but, unlike its sister strain marijuana, it has hardly any THC, the psychoactive substance that gives users a ‘high’. Cognizant of this distinction, the Chinese prohibit any involvement in marijuana and enforce that prohibition with harsh penalties, all while allowing the cultivation and production of hemp. In the U.S., however, generally all cannabis cultivation, production and use is illegal under federal law.

CIIX has already dipped its toes in the cannabis waters with its investment in Medicine Man Technologies, Inc. (OTCQB: MDCL). According to SEC filings, CIIX generated $2.3 million in proceeds from a partial exit of its Medicine Man venture in 2016. Medicine Man Technologies provides consulting services related to cultivation, production, and dispensary operations to clients in 11 U.S. states and Puerto Rico.

In February, CIIX launched what it has described as the first CBD health products online store in the Chinese language. The web site, CBD BIO TECH (http://dtn.fm/J3tq0), is intended to be a retail destination for nutritional supplements containing CBD targeting the Asian market through both online and in-store purchases. The announcement follows CIIX’s plan (http://dtn.fm/tl35G) to launch a Chinese language Yelp-style mobile app for locating dispensaries and discussing cannabis products in the U.S., as well as a December announcement (http://dtn.fm/n1WaL) that it had entered into an alliance with Chinese private equity firm Shenzhen Yuanrong PE Capital to seek out opportunities in medical and recreational cannabis.

Still, there’s more to CIIX than CBD, as the company also operates a consultancy and a financial news service. Services include a variety of information products, web-based tools for investor education, and real-time market commentary, analysis and education in Chinese language character sets.

CIIX was founded in 1999 by Warren Wang, who was born in Shanghai, China. Wang came to the U.S. and later studied finance at St. John’s University in New York. He has served as chief executive officer, chairman of the board, and director of ChineseInvestors.com, Inc. since its inception, with the exception of March 2002 through August 2003, when James S. Toreson served as the company’s chief executive officer as a condition of the Hollingsworth LLC investment.

Wang was previously the vice president of investments for Tradeway Securities Group, a senior financial consultant for Waldron & Co., and a senior account executive at Donald & Co. Securities. He has over 15 years of experience in the financial markets industry and has extensive experience in management, project development, sales, marketing, accounting, and administration. He is a Chartered Financial Analyst (CFA) Candidate, as well as a member of the Market Technicians Association (MTA).

In a recent update, SeeThruEquity increased the price target on CIIX stock to $3.75 to reflect the company’s foray into the cannabis space. The stock is currently quoted at $0.84.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Revenue-generating biosciences company focused on improving the delivery of bioactive compounds through gourmet foods
• Proprietary technology shown to enhance the bioavailability of orally ingested cannabinoids while improving the taste
• Actively developing and selling hemp oil-based gourmet food products through consumer brands ViPova™ and Lexaria Energy

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Fast-growing electronic payments business
• Non-cash payments continue to grow
• Flagship Aptito restaurant management solution

Cash may be king, but Miami, Florida-based fintech Net Element, Inc. (NASDAQ: NETE) seems set on deposing it. The innovative global technology company provides a range of non-cash payment solutions that are increasingly taking the place of cash as consumers expand their use of electronic means of payment. As global adoption of digital payments increases, the company expects its transaction processing business to continue growing at double-digit rates.

According to The Federal Reserve Payments Study 2016 (http://dtn.fm/T1SxD), non-cash payments in the U.S. in 2015, the last year for which data is available, amounted to about $178 trillion, taking the following forms and trillion-dollar amounts: debit cards ($2.56); credit cards ($3.16); checks ($26.83); ACH debits ($54.76) and ACH credits ($90.54). ACH (Automated Clearing House) transactions can be either debits, where someone authorizes a merchant, say, to withdraw funds from a bank account, or credits, where the holder of a bank account instructs his or her bank to transfer funds out of the account.

More details on the non-cash world come to light in the latest World Payments Report (http://dtn.fm/Pp19v), published by consultants Capgemini in collaboration with the French bank BNP Paribas, showing that cash may soon lose its crown. The report discovered that ‘global non-cash transaction volumes grew 11.2% during 2014-15, the highest growth of the past decade…’ For 2015, the last full year of data surveyed, ‘debit cards and credit transfers were the leading’ transaction instruments, with debit cards accounting for 46.7% and credit cards for 19.5% of global non-cash transactions. These are encouraging findings for NETE, since its transaction-solutions unit, which processes debit and credit cards, brings in the lion share of both revenues and income.

NETE’s North America Transaction Solutions unit, its major business division, provides a range of technology and services for retailers to accept cashless payments. These include both card-present (swipe) point-of-sale solutions and card-not-present alternatives, such as mail order or over the phone (MOTO) transactions, also called Merchant Acquiring transactions. The unit also offers mobile payment services, merchant performance analytical tools, merchant back office reporting, and the cloud-based Aptito point-of-sale platform.

Aptito is a unique restaurant point-of-sale product that aims to use mobility to give managers and staff greater control. The Aptito iOS cloud-based platform offers a comprehensive array of management and payment services specially designed for the food and beverage industry. It features digital menus (instead of traditional laminated paper stock ones), mobile point-of-sale (no running back and forth between tables and counter) and a Mobile Communicator that allows wait staff to send orders directly to the bar or kitchen. Aptito will reduce the time and energy wait staff expend going in person from diners to kitchen and back, undoubtedly improving customer service.

According to the latest SEC filing, the transaction-solutions business is doing extremely well. Revenues for the 12 months ended December 31, 2016, were up by 54 percent over same period 2015 revenues. As a result, the unit now contributes 78 percent of sales, up from the 68 percent one year ago.

In a recent update to investors, SeeThruEquity maintained the price target of $2.45 it had set earlier (http://dtn.fm/Vyr2U). Net Element stock, under the symbol NETE, currently trades at $0.50 on the NASDAQ Capital Market.

For more information, visit the company’s website at www.NetElement.com

• Environmental and energy services are creating value and driving growth
• The company is further seeking to increase sales and contracts, grow its staff, and attract capital
• XFUL and three subsidiaries (HCPA, Gilbert, AES) are working together to serve a vast market

Serving oil and gas customers, pipeline customers, and other industrial clients, Converde Energy USA (OTC: XFUL), d/b/a American Energy Partners, and its partners possess a high level of technical expertise that puts the company at a distinct advantage. It provides solutions that can meet the needs of markets that require both energy production and water sourcing, treatment, and supply. Together with its three subsidiaries, XFUL is catering to industries that are reliant on hydraulic fracturing, in which the typical well uses 4.4 million gallons of water. Water is provided from rivers, public utilities, and from recycling and treatment facilities, but the conglomerate is now serving the Marcellus and Utica regions of Pennsylvania and Ohio, where thousands of locations have yet to be drilled.

The company’s partners present a triple-threat to competitors and a boon for investors in the region’s large and growing industrial sector. Hydration Company of PA (HCPA) is an expert in hydrological studies. It has located the largest non-potable water sources in the region, while its negotiation expertise allows it to gain access to these sources from their owners. Conducting its own studies in the hydrological and engineering circuit, it can then obtain permits and install the appropriate filtration. Lastly, HCPA can distribute water sources via its turn-key platform, leveraging the technologies of American Energy Solutions (AES), another subsidiary of American Energy Partners.

Thanks to AES, industrial customers can receive low cost water treatment and distribution. The subsidiary can also manage waste streams such as coal ash, flowback and produced waters, and remediate a range of other industrial processes. Gilbert Oil & Gas, LLC, is a premier well producer and a leader in acquiring land through mineral rights.

Together, this triple-play offers a valuable asset to regional industries, and to investors. It also helps that American Energy Partners is publicly traded and has strategic alliances that can leverage technology and experience. The company’s growth is being fueled by a plan that includes business development, encompassing activities such as water sampling, flow rate confirmation, site layout, and contract finalization. It also has a robust sales forecast and a plan to add personnel as needed. The help of engineers, hydrologists, executives, quality control teams, and salespeople is anticipated for the near future.

Ultimately, the company is looking to raise $20 million in debt and equity offerings to be used toward consulting services, salaries, legal needs, operating costs, working capital, and business development. The demand for water and fuel is likely to increase in multiple industries in the region. Plus, the competition for water given the high rate of industrial activity is opening the door to potential new opportunities.

For more information, visit the company’s website at www.AmericanEnergy-Inc.com

Let us hear your thoughts: Converde Energy USA, Inc. Message Board

• Proprietary system for high volume, low cost production of medicinal algae
• New research on botanical oil products derived from both cannabis and algae
• Combined health benefits of cannabis and algae create new exclusive market

People have always relied on plants as a primary source of medicine and healing. Hundreds of remarkably common plants, herbs, and flowers continue to serve all kinds of important medicinal and health purposes. Various strains of algae offer high concentrations of vitamins, minerals, antioxidants and proteins. Brown algae have been used for weight loss, cancer, fibromyalgia, arthritis, stress, heart disease and high cholesterol. Blue-green algae, scientific studies indicate, offer antiviral, antitumor, antioxidant, anti-inflammatory, anti-allergic, antidiabetic, and antibacterial properties. Recognized as a powerful energy booster, blue-green algae are used for weight loss, hay fever, diabetes, stress, anxiety, depression, and to improve memory and digestive health.

With so many medically beneficial applications, its little wonder that Algae Dynamics Corp. (OTC: ADYNF) has focused on commercialization of its proprietary BiloSilo™ system for the high volume, low cost production of contaminant-free algae biomass. These cost-effective, highly-pure algae biomasses are rich in minerals, prebiotics, vitamins, and other nutritional substances and are exceptionally high in Omega-3 fatty acids, which can be added to a wide range of products. Algae Dynamics’s unique nutraceutical algae oil health products have now expanded to include pharmaceutical cannabis oils. Algae Dynamics has developed a vegetal strategy of producing products that combine the health benefits of both algae and cannabis oils. The synergistic effects of the two plant-based remedies hold tremendous promise, and the ability to sell and cross market the products to health conscious consumers gives the company real competitive advantages.

With an ongoing commitment to science, Algae Dynamics has engaged two Canadian universities to perform research and product development into the use of extracts from cannabis oil combined with the proven health benefits of Omega-3’s derived from algae oil. Research is focused on the use of cannabis oil and Omega-3’s in treatment of cancers and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health.

Algae Dynamics is applying hard science to eons of plant-based medicine and human history to create unique and effective therapeutics that may very well may set a new standard in treating a multitude of ailments and propel the company far beyond expectations. With all that’s happening, it certainly appears that Algae Dynamics is fast on its way to realizing its vision of becoming a global leader in the formulation and development of health products from cannabis derivatives, algae oils and other botanical oils. New therapeutics from ancient remedies would seem certain to be embraced in the marketplace.

For more information, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• China’s digital ad market is booming; Moxian is well-positioned to benefit
• China has 733 million internet users and 691 million smartphone subscribers
• Moxian targets China’s 75 million small- and medium-sized businesses, helping them connect to customers online

As it competes in the expanding sector of online-to-offline (O2O) marketing in China, Moxian, Inc. (NASDAQ: MOXC) is well-positioned to profit from the country’s booming economy.

Developed in China, Moxian provides social marketing and promotion platforms and helps merchants advertise through social media by integrating social media, entertainment, and business intelligence.

More than half of China’s 1.4 billion population use the internet, an estimated 733 million people, and the country boasts 691 million smartphone subscribers.

Moxian focuses on the online-to-offline market, helping offline merchants reach more digitally-oriented customers using promotions such as games, rewards, loyalty programs, and social events.

Targeting the more than 75 million small- and medium-sized businesses in China, Moxian helps companies grow their businesses using consumer behavior data compiled from the company’s database of consumer activities.

The company projects its mobile advertising revenue in China to reach $3 million in 2017 and $6 million in 2018 – which would account for 24% of total company sales.

Digital ad spending in China is expected to grow by 21.5% in 2017, and Moxian stands to benefit. Spending on digital advertising revenue in China has jumped to 57.2% of total ad dollars from just 19.4 percent five years ago.

MOXC is a development stage company currently converting its two O2O platforms from unpaid to paid. The company has two core products: Moxian User App and Moxian Business App.

Moxian+ is a business platform which is already serving, at no charge, some 30,000 small market enterprises (SMEs). It provides merchants with tools to convert customers to members and fans by issuing and redeeming loyalty points, responding to customer inquiries through instant messaging, conducting targeted marketing campaigns and providing listings in a lightweight online store.

Moxian User is a consumer app which already has some 300,000 users and offers social networking features, loyalty points, games, and universal coins for use with any merchant in the Moxian ecosystem.

For more information, visit the company’s website at www.Moxian.com

• Cannabis market could reach $3 Billion by 2021, according to Green Wave Advisors
• Consilium Global Research sees international expansion niche for CIIX
• The Hemp Business Journal projects $450 million in sales from hemp-based products by 2020

ChineseInvestors.com, Inc. (OTCQB: CIIX) stands to benefit from the explosive growth of the cannabis market over the next four years. Cannabis could reach $2.1 billion in consumer sales by 2020, according to Forbes (http://dtn.fm/P5XVw). An optimistic assessment is $3 billion by 2021, according to Green Wave Advisors (www.GreenWaveAdvisors.com).

CIIX offers educational and consulting services to Chinese investors, but, most recently, it has been pursuing a foothold in the cannabis market. In an effort to capitalize on the industry’s lofty projections, CIIX is opening a store in San Gabriel, California, from which to commercialize a line of hemp-oil based products. In addition to its San Gabriel store, the company also owns and operates an online store based in the free trade zone of Shanghai, China.

Research from Outco (http://dtn.fm/wP1u5), a licensed cultivator in Southern California, found that 38% of users and non-users of marijuana said they wanted to learn more about cannabidiol (CBD) oil. A large percentage of those surveyed also indicated that they are bullish on the CBD market, but a myriad of young brands are operating in the cannabis space. According to a report on CIIX from Consilium Global Research (http://dtn.fm/1oA2C), this is a nascent market. The research firm indicated that it will take significant capital to stand out and compete successfully, and resources will be needed to do business within an ever-evolving legal market.

The Consilium report also cited its finding that CIIX’s management team is “seasoned, proven and entrepreneurial,” with the vision and ability to execute. Further, it found positive benefits related to CIIX’s well-ingrained position within the Chinese-speaking community in the U.S. and abroad.

As a result, Consilium sees opportunities for CIIX in international expansion, with its large addressable market and the development of legal cannabis driving multiple years of sustainable growth. Further, the research firm sees the fact that the legal cannabis market has many entrants as an opportunity for CIIX if it can attract the necessary capital to compete.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board